Selected References

  1. Wall ME, Sadler BM, Brine D, et al. Metabolism, disposition, and kinetics of delta-9-tetrahydrocannabinol in men and women. Clin Pharmacol Ther 34:352–363, 1983
  2. Agurell S, Halldin M, Lindgren JE, Ohlsson A,  Widman M, Gillespie H, Hollister L. Pharmacokinetics and metabolism of delta-1-tetrahydrocannabinoids with emphasis on man. Pharmacol Rev 38:21-43, 1986.
  3. Agurell S, Leander K. Stability, transfer and absorption of cannabinoid constituents of cannabis (hashish) during smoking. Acta Pharm Suec 8: 391-402, 1971.
  4. Azorlosa JL, Heishman SJ, Stitzer ML, Mahaffey JM. Marijuana smoking: Effect of varying delta-9-tetrahydrocannabinol content and number of puffs. J Pharmocol Exp Ther 261:114-122, 1992.
  5. Brenneisen R, Egli A, Elsohly MA, et al. The effect of orally and rectally administered delta 9-tetrahydrocannabinol on spasticity: a pilot study with 2 patients. Int J Clin Pharmacol Ther 34 (10): 446-52, 1996.
  6. Burstein B. Biotransformation of the cannabinoids. Barnett G, Chiang CN, eds. Pharmacokinetics and Pharmacodynamics of Psychoactive Drugs. Foster City, CA: Biomedical Publications, 1985. pp. 396-414.
  7. Chiang CW, Barnett G. Marijuana effect and delta-9-tetrahydrocannabinol plasma level. Clin Pharmacol Ther 36 (2): 234-8, 1984.
  8. Frytak S, Moertel CG, Rubin J. Metabolic studies of delta-9-tetrahydrocannabinol in cancer patients. Cancer Treat Rep 68 (12): 1427-31, 1984.
  9. Garrett ER, and Hunt CA. Physicochemical properties, solubility, and protein binding of delta-9-tetrahydro- cannabinol. J Pharm Sci 63(7):1056-1064, 1974.
  10. Gill EW, Jones G. Brain levels of Δ1-tetrahydrocannabinol and its metabolites in mice: correlation with behaviour, and the effect of the metabolic inhibitors SKF 525A and piperonyl butoxide. Biochem Pharmacol 21 (16): 2237-48, 1972.
  11. Goodwin RS, Gustafson RA, Barnes A, Nebro W, Moolchan ET, Huestis MA. D9-Tetrahydrocannabinol, 11-Hydroxy-D9-Tetrahydrocannabinol and 11-Nor-9-Carboxy-D9-Tetrahydrocannabinol in Human Plasma after controlled oral administration of cannabinoids. Ther Drug Monit 28(4), 2006.
  12. Grotenhermen F. Pharmacokinetics and Pharmacodynamics of Cannabinoids. Clin Pharmacokinet 42 (4): 327-360, 2003.
  13. Halldin MM,  Andersson LKR, Widman M, Hollister LE. Further urinary metabolites of delta-1 tetrahydrocannabinol in man. Arzeimittelforsch 32:1135-1138, 1982a.
  14. Halldin MM , Carlsson  S, Kanter SL, Widman M, Agurell S. Urinary metabolites of delta-1-tetrahydrocannabinol in man. Arzeimittelforsch 32:764-768, 1982b.
  15. Halldin MM, Widman M, Bahr CV, Lindgren JE, Martin BR. Identification of in-vitro metabolites of delta-1-tetrahydrocannabinol formed by human liver. Drug Metab and Dispos 10:297-301, 1982c.
  16. Harder S, Rietbrock S. Concentration-effect relationship of delta-9-tetrahydrocannabiol and prediction of psychotropic effects after smoking marijuana. Int J Clin Pharmacol Ther  35 (4): 155-9, 1997.
  17. Harvey DJ. Metabolism and pharmacokinetics of the cannabinoids. In: Watson RR, editor. Biochemistry and physiology of substance abuse. Vol III. Boca Raton (FL): CRC Press279-365, 1991.
  18. Hollister LE, Gillespie HK, Ohlsson A, et al. Do plasma concentrations of delta 9-tetrahydrocannabinol reflect the degree of intoxication? J Clin Pharmacol 21 (8-9 Suppl.): 171S-7S, 1981.
  19. Huestis M. Pharmacokinetics of THC in inhaled and oral preparations. In: Nahas GG, Sutin KM, Harvey D, Agurell S, eds. Marijuana and Medicine. Totowa New Jersey: Humana Press 105-116, 1999.
  20. Hunt CA, and Jones RT. Tolerance and disposition of tetrahydrocannabinol in man. J Pharmacol Exp Ther 215:35-44, 1980.
  21. Karler R, Turkanis SA. Different cannabinoids exhibit different pharmacological and toxicological properties. NIDA Res Monogr 79: 96-107, 1987.
  22. Kreuz DS, Axelrod J. Delta-9-tetrahydrocannabinol: Localization in body fat. Science 179:391-393, 1973.
  23. Kauert GF, Ramaekers  JG, Schneider  E, Moeller  MR, Toennes SW. Pharmacokinetic Properties of delta-9-Tetrahydrocannabinol in Serum and Oral Fluid. J Anal Toxic 31: 288-293, 2007.
  24. Law B, Mason PA, Moffat AC, et al. Forensic aspects of the metabolism and excretion of cannabinoids following oral ingestion of cannabis resin. J Pharm Pharmacol 36 (5): 289-94, 1984.
  25. Lemberger L, Martz R, Rodda B, Forney R, Rowe H. Comparative Pharmacology of A-Tetrahydrocannabinol and its Metabolite, 11-OH-A9-Tetrahydrocannabinol.  J Clinic. Invest. (52): 2411-2417, 1973.
  26. Lemberger L, Weiss JL, Watanabe AM, et al. Delta-9-tetrahydrocannabinol. Temporal correlation of the psychologic effects and blood levels after various routes of administration. N Engl J Med 286 (13): 685-8, 1972b.
  27. Lemberger L. Nabilone, a synthetic cannabinoid of medical utility. In: Nahas GG, Sutin KM, Harvey D, Agurell S eds. Marijuana and medicine. Totowa New Jersey: Human Press, 561-566, 1999.
  28. Lindgren JE, Ohlsson A, Agurell S, et al. Clinical effects and plasma levels of delta 9-tetrahydrocannabinol (delta 9-THC) in heavy and light users of cannabis. Psychopharmacology 74 (3): 208-12, 1981.
  29. McGilveray  IJ. Pharmacokinetics of cannabinoids. Pain Res Manage; 10 (Suppl A): 15A-22A, 2005
  30. Nadulski T, Pragst F, Weinberg G, Roser P, Schnelle M, Fronk EM, Stadelmann AM. Randomized, Double-Blind, Placebo-Controlled Study About the Effects of Cannabidiol (CBD) on the Pharmacokinetics of D9-Tetrahydrocannabinol (THC) After Oral Application of THC Verses Standardized Cannabis Extract. Ther Drug Monit 27:799–810, 2005.
  31. Ohlsson. A, Lindgren JE, Wahlen A, Agurell S, Hollister LE, Gillespie HK. Plasma delta-9-tetrahydrocannabinol concentrations and clinical effects after oral and intravenous administration and smoking. Clinic Pharmacology 28:409-416, 1980.
  32. Ohlsson A, Lindgren, JE, Wahlen A, Agurell S, Hollister LE, Gillespie HK. Single-dose kinetics ofdeuterium-labelled delta-1-tetrahydrocannabinol in heavy and light users. Biomedical Mass Spectrometry 9:6-10, 1982.
  33. Perez-Reyes M, Timmons MS, Lipton MA, Christensen HD, Davis KH, Wall ME. A comparison of the pharmacological activity of delta-9-tetrahydrocannabinol and its monohydroxylated metabolites in man. Experientia 29:1009-1010, 1973.
  34. Perez-Reyes M. Pharmacodynamics of certain drugs of abuse. In: Barnett, G., and Chiang, C.N., eds. Pharmacokinetics and Pharmacodynamics of Psychoactive Drugs. Foster City, CA: Biomedical Publications, 1985. pp. 287-310.
  35. Perez-Reyes M, Timmons M, Lipton M, et al. Intravenous injection in man of delta-9- tetrahydrocannabinol and 11-OH-delta- 9-tetrahydrocannabinol. Science 177 (49): 633-5, 1972.
  36. Perez-Reyes M. Marijuana smoking: Factors that influence the bio-availability of tetrahydrocannabinol. NIDA Res Monogr 99:42-62, 1990.
  37. Perez-Reyes M, Simmons J, Brine D, et al. Rate of penetration of Δ9-tetrahydrocannabinol and 11-hydroxy-Δ9-tetrahydrocannabinol to the brain of mice. In: Nahas GG, editor. Marihuana: chemistry, biochemistry, and cellular effects. New York: Springer179-185, 1976.
  38. Rapaka, R.; Makriyannis, A;NIDA Res Monogr. 1987;79.
  39. Robbe HWJ. Influence of marijuana on driving. Maastricht: Institute for Human Psychopharmacology, University of Limburg, 1994.
  40. Ryrfeldt, A.; Ramsay, C.H.; Nilsson, I.M.; Widman, M.; and Agurell, S. Whole-body autoradiography of delta-1-tetrahydrocannabinol and delta-8-tetrahydrocannabinol in mouse. Acta Pharm Suec 10:13-28, 1973.
  41. Siemens Doyle OL, Pryor GT. Determination of the disposition of 14C-delta-9-tetrahydrocannabinol and 3H-delta-9-tetrahydrocannabinol. Life Sciences 24:1261-1274, 1979.
  42. Sporkert F, Pragst F, Ploner CJ, et al. Pharmacokinetic investigation of delta-9-tetrahydrocannabinol and its metabolites after single administration of 10mg Marinol in attendance of a psychiatric study with 17 volunteers. Poster at the 39th Annual International Meeting, International Association of Forensic Toxicologists; Aug 26-30; Prague, Czech Republic, 2001.
  43. Timpone JG, Wright DJ, Li N, et al. The safety and pharmacokinetics of single-agent and combination therapy with megestrol acetate and dronabinol for the treatment of HIV wasting syndrome. AIDS Res Hum Retroviruses 1997; 13 (4): 305-15.
  44. Wall ME, Sadler BM, Brine D, et al. Metabolism, disposition, and kinetics of delta-9-tetrahydrocannabinol in men and women. Clin Pharmacol Ther 34:352–363, 1983
  45. Wall ME, Perez-Reyes M. The metabolism of delta-9-tetrahydrocannabinol and related cannabinoids in man. J Clin Pharmacol 21:178-189, 1981.
  46. Wall ME, Brine DR, Perez-Reyes M. Metabolism of cannabinoids in man. In: Braude MC, Szara S, editors. Pharmacology of marihuana. New York: Raven Press 93-113, 1976.
  47. Widman M, Agurell S, Ehrnebo M, Jones G. Binding of (+)-and (-)-delta-1-tetrahydrocannabinols and (-)-7-hydroxydelta-1- tetrahydrocannabinol to blood cells and plasma proteins in man.  Journal of Pharmacy and Pharmacology 26(11):914-916, 1974.
  48. Widman M, Halldin MM, Agurell S. Metabolism of delta-1-tetrahydrocannabinol in man. In: Barnett G, Chiang CN, eds. Pharmacokinetics and Pharmacodynamics of Psychoactive Drugs. Foster City, CA: Biomedical Publications, 1985. pp. 415-426.
  49. Romano LL and Hazekamp A. Cannabis Oil: chemical evaluation of an upcoming cannabis-based medicine. Cannabinoids 2013;1(1):1-11.
  50. Robson P. Human Studies of Cannabinoids and Medicinal Cannabis. HEP (2005) 168:719–756.
  51. Izzo AA, Borrelli F, Capasso R, Di Marzo V and
  52. Mechoulam R. Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. Trends Pharmacol Sci. 2009 Dec;30(12):609.

  53. Hampson AJ, Grimaldi M, Axelrod J, and Wink D. Cannabidiol and (2)D9-tetrahydrocannabinol are neuroprotective antioxidants. Proc. Natl. Acad. Sci. USA Vol. 95, pp. 8268–8273, July 1998.
  54. Sativex® product monograph:
  55. Marinol® product monograph: